Etakafusp alfa

N/A

Report date: 2026/05/08 20:02:52

Base Information

Drug NameEtakafusp alfa
Drug Alias NameAB-248
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionCytotoxic T lymphocytes stimulantsInterleukin-2 replacementsCD8-positive T-Lymphocytes stimulants
TargetsInterleukin-2
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth KoreaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaIND
Originator CompaniesAsher Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesWashington University School Of MedicineAmgen IncAsher Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A